32 studies found for:    " July 02, 2008":" August 01, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Lovastatin: Immunomodulatory Value Evaluation
Condition: HIV Seropositivity
Interventions: Drug: Lovastatin;   Other: placebo
2 Completed
Has Results
Safety and Efficacy Study of Switching From Epzicom to Truvada
Condition: HIV Infection
Interventions: Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);   Drug: abacavir (ABC)/lamivudine (3TC)
3 Completed Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand
Condition: HIV Infections
Intervention:
4 Active, not recruiting Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients
Condition: HIV Infection
Interventions: Biological: DermaVir;   Biological: Placebo
5 Completed
Has Results
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
Condition: HIV Infection
Interventions: Biological: DermaVir;   Drug: HAART
6 Active, not recruiting Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
Condition: HIV Infections
Interventions: Behavioral: Skills-Building Intervention;   Behavioral: Personal Interview Group
7 Completed Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
Condition: HIV Infections
Intervention: Drug: Addition of raltegravir 800 mg QD to HAART
8 Completed
Has Results
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Conditions: Chronic Hepatitis C;   Hepatitis C;   HIV Infections
Interventions: Biological: PEG-IFN alfa-2b;   Drug: RBV
9 Completed Healthy Activities for Prize Incentives
Conditions: Substance Abuse;   HIV Infections
Intervention: Behavioral: contingency management
10 Unknown  Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais
Condition: HIV Infections
Intervention:
11 Completed Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families
Condition: HIV Infections
Interventions: Behavioral: Family Centered Advanced Care Planning (FCACP) sessions;   Behavioral: Health education control sessions
12 Completed
Has Results
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Condition: Human Immunodeficiency Virus (HIV) Infection
Interventions: Drug: Maraviroc;   Drug: Ritonavir;   Drug: Saquinavir
13 Completed Impact of an HPV Vaccine in HIV-Infected Young Women
Condition: HIV Infection
Intervention: Biological: HPV vaccine for strains -6, -11, -16, and -18
14 Completed The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
Conditions: HIV Infection;   Bone Mass
Intervention: Dietary Supplement: cholecalciferol plus calcium carbonate
15 Enrolling by invitation Cerebrospinal Fluid (CSF) Raltegravir Substudy
Condition: HIV Infections
Intervention:
16 Completed GSK706769/KALETRA Drug-drug Interaction Study
Conditions: Healthy Subjects;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK706769 & KALETRA
17 Completed
Has Results
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Condition: Human Immunodeficiency Virus Infection
Interventions: Drug: lopinavir/ritonavir (LPV/r);   Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF);   Drug: raltegravir (RAL)
18 Active, not recruiting Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART
Conditions: HIV Infections;   Malaria
Interventions: Drug: Lamivudine;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Zidovudine
19 Completed
Has Results
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
Condition: HIV Infections
Intervention:
20 Completed Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
Condition: HIV Infections
Intervention: Drug: Maraviroc

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years